Fig. 6

In vivo effective antitumor and anti-angiogenesis of Lf-GL in orthotopic GBM mouse model. a Schematic illustration of treatment plan. b Immunofluorescence staining of HMGB1, VEGF, CD31, and Ki67 in GBM tissues after 14 days of treatment. Scale bar: 100 μm. c Quantification of HMGB1 mean fluorescence intensity (MFI). Data are expressed as mean ± S.E.M (n = 3). **P < 0.01 and ***P < 0.001. d Quantification of VEGF mean fluorescence intensity (MFI). Data are expressed as mean ± S.E.M (n = 3). *P < 0.05 and **P < 0.01. e Quantification of CD31 mean fluorescence intensity (MFI). Data are expressed as mean ± S.E.M (n = 3). **P < 0.01 and ***P < 0.001. f Quantification of Ki67 mean fluorescence intensity (MFI). Data are expressed as mean ± S.E.M (n = 3) **P < 0.01 and ***P < 0.001. g Nissl and H&E staining. White dashed lines in Nissl staining represents the GBM area of the whole brain. Red dashed line in H&E staining represents the boundary between the tumor and normal regions. Scale bar: 100 μm. h TUNEL assay of PBS-vehicle- (Control), Lf-, GL-, and Lf-GL-treated group. Red dashed line represents the boundary between the tumor and normal regions. Red arrows indicate tumor infiltration into surrounding tissues. Scale bar: 100 μm. i Proportion of GBM in the brain after treatment. Data are expressed as mean ± S.E.M (n = 4). ***P < 0.001 versus Control. j Counts of necrotic areas on the H&E staining. Data are expressed as mean ± S.E.M (n = 4). ***P < 0.001. k Quantification of TUNEL mean fluorescence intensity (MFI). Data are expressed as mean ± S.E.M (n = 4). **P < 0.01 and ***P < 0.001